Compare AZI & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AZI | BRTX |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | | Managed Health Care |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 9.7M |
| IPO Year | 2024 | N/A |
| Metric | AZI | BRTX |
|---|---|---|
| Price | $0.06 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 52.3M | 81.9K |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $156,466,000.00 | $383,400.00 |
| Revenue This Year | N/A | $112.14 |
| Revenue Next Year | N/A | $139.81 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 32.90 | 1.70 |
| 52 Week Low | $0.05 | $0.98 |
| 52 Week High | $1.38 | $2.55 |
| Indicator | AZI | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 29.27 | 38.55 |
| Support Level | $0.05 | $0.98 |
| Resistance Level | $0.06 | $1.17 |
| Average True Range (ATR) | 0.01 | 0.13 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 8.95 | 27.05 |
Autozi Internet Technology (Global) Ltd provides high-quality, affordable, and professional one-stop automotive products and services through online and offline channels in China. Leveraging its online supply chain cloud platform, SaaS platforms, and the network of MBS stores, It has established an ecosystem of lifecycle automotive services by connecting automotive manufacturers, auto parts manufacturers, and insurance companies with MBS stores and various automotive owners. Its business segments include new car sales, auto parts and auto accessories sales, and automotive insurance-related services. The majority of revenue is from the new car sales segment, and auto parts & auto accessories sales.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.